Q1 EPS Estimate for Gain Therapeutics Lifted by Analyst

Gain Therapeutics, Inc. (NASDAQ:GANX) – Analysts at HC Wainwright upped their Q1 2026 earnings per share estimates for shares of Gain Therapeutics in a research report issued on Monday, March 30th. HC Wainwright analyst R. Selvaraju now forecasts that the company will earn ($0.13) per share for the quarter, up from their prior forecast of ($0.15). HC Wainwright has a “Buy” rating and a $8.00 price target on the stock. The consensus estimate for Gain Therapeutics’ current full-year earnings is ($1.00) per share. HC Wainwright also issued estimates for Gain Therapeutics’ Q2 2026 earnings at ($0.13) EPS, Q4 2026 earnings at ($0.11) EPS, FY2026 earnings at ($0.50) EPS, Q1 2027 earnings at ($0.12) EPS, Q2 2027 earnings at ($0.12) EPS, Q3 2027 earnings at ($0.13) EPS, Q4 2027 earnings at ($0.11) EPS and FY2027 earnings at ($0.47) EPS.

Gain Therapeutics (NASDAQ:GANX) last announced its earnings results on Thursday, March 26th. The company reported ($0.11) EPS for the quarter, topping the consensus estimate of ($0.14) by $0.03.

A number of other equities research analysts also recently commented on GANX. Roth Mkm reiterated a “buy” rating and issued a $10.00 price objective on shares of Gain Therapeutics in a report on Friday, December 19th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Gain Therapeutics in a research report on Monday, December 29th. Four investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $8.50.

Gain Therapeutics Stock Down 4.6%

Shares of NASDAQ GANX opened at $1.85 on Wednesday. Gain Therapeutics has a 1 year low of $1.41 and a 1 year high of $4.34. The firm’s 50-day moving average is $2.12 and its 200-day moving average is $2.37. The company has a current ratio of 6.63, a quick ratio of 6.63 and a debt-to-equity ratio of 0.02. The firm has a market capitalization of $78.14 million, a PE ratio of -3.03 and a beta of 0.11.

Hedge Funds Weigh In On Gain Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of the business. Marshall Wace LLP increased its stake in Gain Therapeutics by 849.3% during the 4th quarter. Marshall Wace LLP now owns 1,662,293 shares of the company’s stock worth $5,353,000 after purchasing an additional 1,487,186 shares in the last quarter. Potomac Capital Management Inc. bought a new position in Gain Therapeutics in the fourth quarter valued at approximately $3,252,000. Jane Street Group LLC lifted its stake in Gain Therapeutics by 234.5% in the fourth quarter. Jane Street Group LLC now owns 242,328 shares of the company’s stock valued at $780,000 after buying an additional 169,878 shares in the last quarter. LPL Financial LLC acquired a new position in shares of Gain Therapeutics in the fourth quarter valued at approximately $343,000. Finally, State Street Corp increased its position in shares of Gain Therapeutics by 72.9% during the fourth quarter. State Street Corp now owns 157,537 shares of the company’s stock worth $507,000 after acquiring an additional 66,400 shares in the last quarter. 11.97% of the stock is currently owned by institutional investors and hedge funds.

Key Stories Impacting Gain Therapeutics

Here are the key news stories impacting Gain Therapeutics this week:

• Positive Sentiment: HC Wainwright reiterated a “Buy” rating and a $8.00 target and raised several near‑term EPS assumptions (e.g., Q4 2026 from ($0.13) to ($0.11); FY2026 from ($0.55) to ($0.50)). This is supportive for longer‑term upside vs. the current share price. MarketBeat HC Wainwright note
• Neutral Sentiment: HC Wainwright published detailed quarter-by-quarter loss forecasts across 2026–2027 (Q1–Q4 2026 generally ~($0.13)/quarter; FY2026 ~($0.50); FY2027 ~($0.47)). These provide a clearer roadmap for modeled cash burn and progress but are still projections rather than confirmed operational results. MarketBeat HC Wainwright estimates
• Negative Sentiment: Despite the upward revisions, estimates still show continued losses (HCW FY2026/FY2027 remain negative and well below breakeven), leaving the name dependent on clinical progress or financing news for major re-rating. That ongoing unprofitability and limited near-term catalysts help explain why the stock fell today. MarketBeat HC Wainwright coverage

Gain Therapeutics Company Profile

Gain Therapeutics, Inc (NASDAQ: GANX) is a clinical-stage biopharmaceutical company focused on precision therapeutics for neurodegenerative and rare diseases. The company leverages its proprietary allosteric modulation platform, AlphaTarget, to discover and optimize small molecule modulators that bind to non-active sites on target proteins. By correcting protein folding and function, Gain aims to provide disease-modifying treatments with improved selectivity and reduced off-target effects.

Gain’s lead clinical candidate, GT-022, is being developed for Gaucher disease, a rare lysosomal storage disorder characterized by deficient enzyme activity.